Unresectable Malignant Neoplasm: Clinical Trials

7 trials for Unresectable Malignant Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 recruiting, 1 unknown, 1 withdrawn. 7 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Recruiting 1, Unknown 1, Withdrawn 1
Phase 13Recruiting 1, Unknown 1, Withdrawn 1

Follow Unresectable Malignant Neoplasm: new trials by email Literature Review of Unresectable Malignant Neoplasm trials Research Report on Unresectable Malignant Neoplasm

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
Radiotherapy, Nimotuzumab, S-1 - Esophageal Cancer, Chemoradiotherapy
Phase 2CompletedCancer Institute and Hospital, Chinese Academy of Medical Sciences552019-11-142024-05-16
Chemoradiotherapy in Unresectable Esophageal Cancer
Radiotherapy, Albumin-Bound Paclitaxel, Cisplatin - Esophageal Cancer, Chemoradiotherapy
Phase 1 / Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1052019-10-012024-12-13
ImmunoPET With an Anti-CD8 Imaging Agent
Anti-CD8 PET imaging agent - Metastatic Cancer, Unresectable Malignant Neoplasm
Phase 1 / Phase 2UnknownUniversity Medical Center Groningen472019-02-142024-05-03
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
Durvalumab, IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU) - Esophagus Cancer, Unresectable Malignant Neoplasm
Phase 2CompletedUNICANCER1122018-12-052025-11-18
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Aldoxorubicin Hydrochloride, ALT-803, ETBX-051 - Chordoma, Unresectable Malignant Neoplasm
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2018-08-312025-02-21
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
Atezolizumab, Cobimetinib - Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma
Phase 2CompletedM.D. Anderson Cancer Center492017-04-072025-05-28
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Pembrolizumab - Unresectable Malignant Neoplasm, Melanoma
Phase 2CompletedSt. Louis University102015-01-012019-06-20

Narrower conditions

Esophageal Neoplasms (3)  ·  Neoplasm Metastasis (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma, Mucinous (1)  ·  Carcinoma, Squamous Cell (1)  ·  Chordoma (1)  ·  Melanoma (1)  ·  Neoplasms (1)

Broader conditions

Neoplasms (6)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms by Site (4)  ·  Digestive System Diseases (3)  ·  Digestive System Neoplasms (3)  ·  Esophageal Diseases (3)  ·  Gastrointestinal Diseases (3)  ·  Gastrointestinal Neoplasms (3)  ·  Head and Neck Neoplasms (3)  ·  Carcinoma (2)  ·  Neoplasms, Germ Cell and Embryonal (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Neoplastic Processes (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)

Interventions

Radiotherapy (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  ALT-803 (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Cetuximab (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Fluorouracil (1)  ·  Leucovorin (1)  ·  Oxaliplatin (1)  ·  Platinum (1)  ·  S 1 (combination) (1)  ·  atezolizumab (1)  ·  avelumab (1)  ·  cobimetinib (1)

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)  ·  ImmunityBio, Inc. (1)  ·  M.D. Anderson Cancer Center (1)  ·  St. Louis University (1)  ·  UNICANCER (1)  ·  University Medical Center Groningen (1)

Countries

United States (3)  ·  China (2)  ·  France (1)  ·  Netherlands (1)

Top investigators

Anouchka Modesto, Doctor (1)  ·  E. G.E. de Vries, MD, PhD (1)  ·  John M Richart, MD (1)  ·  Kanwal P Raghav (1)  ·  Laurent Quero, Doctor (1)  ·  Xin Wang, MD (1)

Results publications

PMID 36271158, PMID 36471036

NIH funding

2018 (1)